Popular Press

Call us Now

+41 44 741 8181

Call Back

Request Here

Make Appointment

Come to us @ ELZA

Email Us

info@elza-institute.com

Recommend Us

Thank you!

Telemedicine

Online consultation

  • Farhad Hafezi, Popular press
New therapy for Terrien’s Marginal Degeneration
“We only treated two eyes, but it was the first time a Terrien could be stopped and partially reversed,” Farhad Hafezi, MD, PhD, OSN Europe Edition Board Member, said in a telephone interview with Ocular Surgery News
  • by Prof. Farhad Hafezi
  • November 1, 2014
Read More
  • Farhad Hafezi, Popular press
CXL: Limbus illumination is safe
CXL Excels. Two studies demonstrate the safety and potential of decentered corneal collagen cross linking.
  • by Prof. Farhad Hafezi
  • September 6, 2014
Read More
  • Farhad Hafezi, Popular press
Cross-Linking only works when sufficient oxygen is present
The success of corneal crosslinking (CXL) for ectatic disease requires oxygen within the tissue, and this dependency likely explains the limited efficiency of high-intensity (rapid) and transepithelial treatment protocols, said Farhad Hafezi, MD, PhD
  • by Prof. Farhad Hafezi
  • July 11, 2014
Read More
  • Farhad Hafezi, Nikki Hafezi, Popular press
PACK-CXL For All
The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis is compelling
  • by Prof. Farhad Hafezi
  • May 15, 2014
Read More
  • Farhad Hafezi, Popular press
The PowerList 2014
In 2014, the readers of “The Ophthalmologist” voted for the PowerList, the 100 most influential personalities in global ophthalmology. ELZA member Farhad Hafezi is one of them.
  • by Prof. Farhad Hafezi
  • April 26, 2014
Read More
PREV1011121314Next
.
.